This afternoon we watched Centene rise 2.4% to a price of $59.42 per share. The Large-Cap Medical Specialities company is now trading -25.84% below its average target price of $80.13. Analysts have set target prices ranging from $52.0 to $93.0 per share for Centene, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 3.7%, and a short ratio of 2.68. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.7% of Centene's shares being owned by this investor type.
Institutions Invested in Centene
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Norges Bank Investment Management | 0% | 21,212,326 | $1,260,436,372 |
| 2024-09-30 | Geode Capital Management, LLC | 0% | 12,656,962 | $752,076,658 |
| 2024-09-30 | Vanguard Group Inc | 0% | 60,082,139 | $3,570,080,589 |
| 2024-09-30 | FMR, LLC | 0% | 24,570,510 | $1,459,979,659 |
| 2024-09-30 | Capital World Investors | 0% | 22,566,201 | $1,340,883,622 |
| 2024-09-30 | Blackrock Inc. | 0% | 45,608,071 | $2,710,031,495 |
| 2024-09-30 | Harris Associates L.P. | 0% | 26,314,183 | $1,563,588,705 |
| 2024-09-30 | State Street Corporation | 0% | 23,468,159 | $1,394,477,964 |
| 2024-09-30 | Politan Capital Management LP | 0% | 12,135,044 | $721,064,292 |
| 2024-09-30 | Wellington Management Group, LLP | 0% | 17,327,020 | $1,029,571,496 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Centene.
